Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.100 Biomarker phenotype BEFREE Motor symptoms correlated negatively with striatal DAT BRs. 31790878 2020
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.100 Biomarker phenotype BEFREE Agonist activation of D3R increases dopamine concentration, decreases α-Syn accumulation, enhances secretion of brain derived neurotrophic factors (BDNF), ameliorates neuroinflammation, alleviates oxidative stress, promotes neurogenesis in the nigrostriatal pathway, interacts with D1R to reduce PD associated motor symptoms and ameliorates side effects of levodopa (L-DOPA) treatment. 31765822 2020
Entrez Id: 6647
Gene Symbol: SOD1
SOD1
0.100 AlteredExpression phenotype BEFREE Furthermore, Sod1-Tg mice that are administered AM are found to accumulate AM-associated nicotinamide in the central nervous system, and systemic supplementation of nicotinamide improves motor symptoms and gene expression patterns in the spinal cord of Sod1-Tg mice. 31330533 2019
Entrez Id: 23263
Gene Symbol: MCF2L
MCF2L
0.100 Biomarker phenotype BEFREE Clinical trials have established subthalamic deep-brain-stimulation (STN-DBS) as a highly effective treatment for motor symptoms of Parkinson disease (PD), but in clinical practice outcomes are variable. 30839077 2019
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker phenotype BEFREE The whole group (n = 36) was assessed using motor, non-motor symptoms (sleep disturbances in particular) and quality of life measures (QoL), before surgery, 6 and 12 months after DBS programming. 30975618 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.100 GeneticVariation phenotype BEFREE After a mean follow-up of 3.5 ± 2.1 years, PD patients with baseline pS129-α-synuclein > 8.5 fg/mL were at higher risk of motor symptom progression of at least 3 points in the MDS-UPDRS part III scores than those with pS129-α-synuclein < 8.5 fg/mL (<i>p</i> = 0.03, log rank test). 31623323 2019
Entrez Id: 23263
Gene Symbol: MCF2L
MCF2L
0.100 Biomarker phenotype BEFREE The whole group (n = 36) was assessed using motor, non-motor symptoms (sleep disturbances in particular) and quality of life measures (QoL), before surgery, 6 and 12 months after DBS programming. 30975618 2019
Entrez Id: 23263
Gene Symbol: MCF2L
MCF2L
0.100 Biomarker phenotype BEFREE However, the effect of aDBS on motor symptoms and stimulation-induced side effects during the chronically implanted phase (after the stun effect of DBS placement has disappeared) has not yet been determined. 31201193 2019
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker phenotype BEFREE Clinical trials have established subthalamic deep-brain-stimulation (STN-DBS) as a highly effective treatment for motor symptoms of Parkinson disease (PD), but in clinical practice outcomes are variable. 30839077 2019
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.100 Biomarker phenotype BEFREE The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. 31306141 2019
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker phenotype BEFREE A dramatic improvement in motor symptoms was equally observed in both groups of patients after DBS. 31028845 2019
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.100 Biomarker phenotype BEFREE Relations of non-motor symptoms and dopamine transporter binding in REM sleep behavior disorder. 31664065 2019
Entrez Id: 23263
Gene Symbol: MCF2L
MCF2L
0.100 Biomarker phenotype BEFREE A dramatic improvement in motor symptoms was equally observed in both groups of patients after DBS. 31028845 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.100 Biomarker phenotype BEFREE Deletion and/or deficiency of α-synuclein does not influence clinical and neuropathological disease progression in murine MPS IIIA, demonstrating that in and of itself, this protein does not initiate the cognitive and motor symptoms that occur in the first 5 months of life in MPS IIIA mice. 30907009 2019
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker phenotype BEFREE However, the effect of aDBS on motor symptoms and stimulation-induced side effects during the chronically implanted phase (after the stun effect of DBS placement has disappeared) has not yet been determined. 31201193 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.100 Biomarker phenotype BEFREE During the course of disease, misfolded α-synuclein, the major constituent of LB, spreads to different regions of the brain in a prion-like fashion, giving rise to successive non-motor and motor symptoms. 31428316 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.100 GeneticVariation phenotype BEFREE Our study shows for the first time that SNCA rs11931074 polymorphism might modulate brain functional alterations and correlate with motor symptoms in Chinese PD patients. 31243602 2019
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.100 GeneticVariation phenotype BEFREE The presence of serotonergic pathology in premotor A53T SNCA carriers preceded development of dopaminergic pathology and motor symptoms and was associated with disease burden, highlighting the potential early role of serotonergic pathology in the progression of Parkinson's disease. 31229470 2019
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker phenotype BEFREE However, little is known about the initial effects of STN-DBS on nonmotor domains.Our objective was to elucidate the initial effects of STN-DBS on non-motor and motor symptoms in PD patients in a 4-month follow-up.This open prospective study followed 24 patients with PD who underwent STN-DBS. 29384860 2018
Entrez Id: 6622
Gene Symbol: SNCA
SNCA
0.100 Biomarker phenotype BEFREE α-synuclein aggregation is hypothesised to start in autonomic nerve terminals years before the appearance of motor symptoms, and subsequently spread via autonomic nerves to the spinal cord and brainstem. 29866443 2018
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.100 Biomarker phenotype BEFREE We recruited 32 patients with early-stage PD and 28 control subjects, and evaluated parkinsonian motor symptoms and dopamine transporter imaging data. 30442917 2018
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker phenotype BEFREE This study aims to investigate how the frequency settings of deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) influence the motor symptoms of Parkinson's disease (PD). 30262859 2018
Entrez Id: 6531
Gene Symbol: SLC6A3
SLC6A3
0.100 Biomarker phenotype BEFREE Urinary dysfunction in untreated PD is related with increase in motor symptoms (especially bradykinesia and axial symptoms) and reduction of striatal DAT availability. 29449184 2018
Entrez Id: 6647
Gene Symbol: SOD1
SOD1
0.100 Biomarker phenotype BEFREE In transgenic mice overexpressing disease-causing human SOD1<sup>G37R</sup> or SOD1<sup>G93A</sup> mutations, treatment with the α-miSOD1 antibody delayed the onset of motor symptoms, extended survival by up to 2 months, and reduced aggregation of misfolded SOD1 and motor neuron degeneration. 30518612 2018
Entrez Id: 4036
Gene Symbol: LRP2
LRP2
0.100 Biomarker phenotype BEFREE Given that bilateral STN DBS is at least as effective as bilateral GPi DBS in treating motor symptoms of Parkinson's disease (as measured by improvements in UPDRS-III scores), consideration can be given to the selection of either target in patients undergoing surgery to treat motor symptoms.(Level I). 29538685 2018